Issue link: http://osercommunicationsgroup.uberflip.com/i/247183
Sunday, August 11, 2013 Chain Drugstore Daily Amneal (Cont'd. from p. 1) manufacturer, marketer, and distributor of generic drugs. Tell us about the company's key achievements of the past year. CP: I'm very pleased to share Amneal's latest accomplishments. We've maintained exceptional growth following the 2007 launch of our label in the marketplace and opportunistic acquisitions. Amneal is still the seventh largest U.S. generics manufacturer based on number of prescriptions dispensed, according to March 2013 IMS Health data, with a five-year CAGR of almost 38 percent. We're among the fastest-growing generic companies in the U.S. with eight of our top 10 products No. 1 in their respective markets. Amneal has received numerous accolades from customer and industry associations for our track record of outstanding growth, superior service, and adherence to the highest standards of HD Smith (Cont'd. from p. 1) for the patient, H. D. Smith is nimble and flexible enough to tailor their services to each customer's needs. In H. D. Smith's world, "one size does not fit all." "Our customers are the center of everything we do – and our ability to collaborate with them, to develop custom solutions and services, makes a significant impact on their businesses and the patients and communities they serve," said Dale Smith, Chairman and CEO of H. D. Smith. "We answer to our customers' needs above all else. Our focus on meeting each customer's needs is what sets us apart from other pharmaceutical wholesalers – and that means not only collaborating, but expanding our offerings to support customers in a changing marketplace." In the retail pharmacy sector, H. D. Smith is responding to customer needs Actavis (Cont'd. from p. 1) Watson's acquisition of Actavis in late 2012, the company adopted the Actavis name, but refreshed the legacy brand by creating a dynamic new logo and brand identity. CDD: Watson was a recognized name in the U.S. generics industry. What is the rationale behind the name change? AB: The new Actavis now has a commercial footprint that spans more than 62 markets around the world. While Watson had established a strong reputation within the U.S., registering the name in global markets presented significant challenges due to the commonality of the name "Watson." Working with world renowned Uniweb (Cont'd. from p. 4) scheme; a vast variety of accessory options; laminate or Uniweb panels on the exterior for increased display possibilities; millwork; and unlimited options for accessories! Uniweb creates these rooms and quality. In June, we were presented HDMA's DIANA Award for Best Generic Manufacturer (Sales over $100M/sales under $100M). We were also honored as the first-ever HDMA Partner of the Year. CDD: How will Amneal drive market leadership over the next five years? CP: Amneal's well-balanced product portfolio counts 65 FDA-approved drugs across multiple therapeutic areas. Our large and diversified pipeline contains 219 small-molecule generics currently in development or filed and awaiting FDA approval; 22 percent are eFTF, FTF, and FTM filings, while 33 percent are Paragraph IV products. Our efficient allocation of R&D resources targets the most attractive commercial products across multiple dosage forms, including tablets, capsules, softgels, and oral liquids plus differentiated generics such as injectables, topicals, transdermals, transmucosals, inhalers, nasal sprays, oph- with the design and delivery of significant enhancements to the company's ordering platform, the creation of Marketing Services (an advertising agency) and the launch of ePresence (a state-of-the-art web presence platform). In the manufacturing sector, the company recently collaborated with customers to create a third-party logistics program and a critical supply shortage program. With both of these offerings, key customers were not satisfied with what was available in the market. Each sought out a partner to collaboratively develop a slightly unique offering. Each selected H. D. Smith as their partner. The company has also been focused on expanding its offerings to support pharmaceutical manufacturers. Noting an unmet need in the marketplace – manufacturers' desire to create an enhanced patient experience – H. D. branding consultancy firm Lippincott, we assessed numerous renaming options and it quickly became clear that Actavis, which was already registered around the globe and had a wellestablished reputation in European markets, represented the smartest and best option. CDD: How will the name change affect U.S. customers? AB: We have developed a phased approach to the renaming/rebranding project to ensure minimal impact to our customers. We began by completing the integration of legacy Watson and Actavis key commercial ordering/processing /billing/distribution functions into one streamlined entity within the first 100 days. many other space-efficient concepts to work in combination with your existing footprint. These units provide flexibility while giving you the freedom to design and equip your space for maximum utility and appearance at an affordable price. As your needs change, so can your modular 69 thalmics, and biologics. In all, 92 pipeline products are expected to launch over the next three years, representing an aggregate market size of $62 billion. We're aggressively expanding into high-value and difficult-to-formulate specialty generics and biosimilars while maintaining a meaningful presence in high-volume commodity medicines. Complex generic dosage forms remain underrepresented in the market but are forecasted to lead new product launch opportunities. Over the next five years, differentiated generics valued at $36 billion in worldwide annual sales and biologics worth almost $80 billion will lose patent protection. With continued margin compression on commodity products, these advanced medications will be critical differentiators for Amneal going forward. how is Amneal capitalizing on this phenomenon? Smith secured majority ownership position of Triplefin, a reimbursement, patient assistance and pharmaceutical brand-support services company. Like H. D. Smith, Triplefin is a company committed to collaboration and partnership through the delivery of innovative and customized solutions. By combining the two companies' expert capabilities and passion for customer service, H. D. Smith is better able to help prescription manufacturer customers ensure their products get to market, reaches patients, that the necessary educational programs and nursing support to patients are in place, and that they obtain compliance and outcomes data that manufacturers and insurers all desire. "Our vision since 1954 has been to provide the best possible all-around support to customers and their patients. With Triplefin, the H. D. Smith offering expands far beyond a 'pick, pack, and ship' wholesale business to a full-line, broad services pharmaceutical solutions provider that supports more efficient operations through responsive, targeted and relevant business solutions," Smith explained. "We are building a foundation for success by gaining better knowledge and understanding of our customers, their needs, and the way they want to do business. This allows us to provide our customers with a distinct and clear value proposition," he added. Blending customer knowledge with the solutions and services they can now offer makes H. D. Smith an ideal partner in today's everchanging marketplace. CDD: We hear a lot about the "patent cliff", i.e. brand pharmaceuticals losing patent protection over the next several years. As a producer of generics, We then focused on legally renaming the integrated commercial/distribution entity from Watson Pharma, Inc. to Actavis Pharma, Inc., which now handles all of our U.S. generics business. Our teams are now working through the final phase of the project - the conversion of our legacy Watson manufacturing entities and including the associated regulatory filings necessary to convert to Actavis. Throughout this process we are committed to communicating with our customers and to delivering the same level of industry-leading service customers expect from the new Actavis. CDD: When will customers begin to see newly labeled Actavis products in the U.S.A? AB: Our legacy Watson and Actavis room! Whether you need more space or need to change your operation's layout, you are not locked into your original design. Call Uniweb today. Sales professionals will be proud to show you satisfied customers' current installations, take you on a tour of the new, state-of- CP: As patents on blockbuster brands expire, sales of these expensive, highvolume medications will decline, dramatically impacting pharmacy sales and profits. We see tremendous opportunity in diversifying our portfolio with complex FTM generics, biosimilars, novel drugs and technologies, and advanced dosage forms. This strategy should continue to supply pharmacies with the highmargin generic products their profits have depended upon. By offering a balanced portfolio of high-volume and high-value medications enhanced with non-product/price value to maximize real benefits for our customers, Amneal has become Generics' next generation—pharma's antidote to the patent cliff. Visit Amneal at booth 2624 at the NACDS Total Store Expo, www.amneal.com, or call the company at 866-525-7270. For more information, visit booth 5216 at the Total Store Expo, go online to www.hdsmith.com, call 866-232-1222 or email at inquiry@hdsmith.com. entities in the U.S. are the manufacturing and product regulatory filing holders for the majority of products distributed in the U.S. today. To enable the conversion of legacy, Watson and Actavis labeled product to the new Actavis logo, we are first focusing on the legal aspects of the renaming and associated regulatory filings. We expect to begin a phased conversion of legacy Watson and Actavis product labeling to the new Actavis label in 2014. As always, we are committed to customer communications and will ensure our customers are notified throughout this process. Learn more about the new Actavis at NACDS booth 2121 or visit www.actavis.com. the-industry 180,000 sq. ft. manufacturing facility, and meet with your team to start discussions on your next remodel project. For more information, visit booth 2112, call 800-486-4932, or visit www .uniwebinc.com.